CUPERTINO, Calif., Sept. 6, 2016 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) announced today that Matt
Hogan, Chief Financial Officer, will be presenting at the
Rodman & Renshaw Global Investment Conference on Monday, September 12 at 9:35 a.m. Eastern Time. The conference is
being held at the Lotte New York Palace Hotel in New York
City. Institutional investors and analysts that are attending
the conference may request a one-on-one meeting through the
conference coordinators.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/rrshq26/drrx.
A live audio webcast of the presentation will also be available
by accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenomic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 1 development, is the lead candidate in DURECT's
Epigenomic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 plays an important regulatory
role in lipid homeostasis, inflammation, and cell survival, and may
have applications related to acute organ injury and chronic
metabolic disease, notably nonalcoholic fatty liver disease (NAFLD)
and nonalcoholic steatohepatitis (NASH). DURECT's advanced
oral, injectable, and transdermal delivery technologies enable new
indications and enhanced attributes, such as abuse deterrence,
extended dosing intervals, and superior safety and efficacy, for
small-molecule and biologic drugs. Late-stage development programs
in this category include POSIMIR® and REMOXY®
ER, addressing key unmet needs in pain management. For more
information, please visit www.durect.com.
NOTE: POSIMIR®, SABER® and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, REMOXY ER and DUR-928 are investigational drugs under
development and have not been approved for sale by the U.S. Food
and Drug Administration or other health authorities.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/durect-to-present-at-the-rodman--renshaw-global-investment-conference-300322349.html
SOURCE DURECT Corporation